CVC Business Summary

CVC Technologies Inc. (4744.TWO) operates a manufacturing-driven business model, generating revenue through the design, assembly, and global sale of automated pharmaceutical packaging equipment and integrated production line solutions. The company’s primary business segments include tablet and capsule counting lines, liquid filling systems, and powder packaging machinery, which are complemented by its 2023 acquisition of Changsung Softgel System, adding specialized softgel encapsulation technology to its portfolio. CVC derives approximately 95% of its revenue from international markets, with a dominant presence in North America and India. In the competitive landscape, CVC contends with global leaders such as IMA Group, Uhlmann Pac-Systeme, and Bausch+Ströbel, positioning itself as a high-tier provider that offers European-grade precision and regulatory compliance at a competitive price point relative to traditional Western incumbents. The company is currently led by Chairman Lin Jing-Yi, who oversees strategic expansion and group development, and General Manager (CEO) Kevin Chang, an executive with deep expertise in industrial automation and pharmaceutical machinery. The leadership team also includes Vice General Manager He Ming-Lie and Chief Financial Officer Chang Jin-Jia, who manage the firm’s operational scaling and financial governance. CVC’s board and ownership structure are anchored by major institutional investors, most notably Dexin Investment Co., Ltd., which serves as a key corporate shareholder. Since its evolution from the 1979-founded K&K and its subsequent 2018 listing on the TPEx, the management has focused on transitioning the firm into a high-end medtech equipment provider, recently prioritizing R&D in AI-integrated inspection systems and the next-generation U2 series machinery.